APRE - Company ID 0001781983
Aprea Therapeutics, Inc. trades as APRE. This page tracks Aprea Therapeutics, Inc. through 425 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| 424B7 | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| EFFECT | - | 2026-04-29 |
The largest companies sharing Aprea Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Aprea Therapeutics, Inc. reported a net loss of $12.60M.